Ibrutinib Significantly Enhances Programmed Cell Death and Overall Survival in Burkitt Lymphoma (BL) NSG Xenografts: A Pre-clinical Study

Authors

T Shah
Yaya Chu, New York Medical CollegeFollow
Sanghoon Lee, New York Medical CollegeFollow
Changhong Yin, New York Medical CollegeFollow
M Barth
R Miles
J AyelloFollow
E Morris
L HarrisonFollow
C van de Ven
S Goldman
M Lim
M Hermiston
S Perkins
Mitchell Cairo, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

June 2017

Journal Title

Pediatric Blood & Cancer

Department

Pediatrics

Second Department

Epidemiology and Community Health

Recommended Citation

Shah, T., Chu, Y., Lee, S., Yin, C., Barth, M., Miles, R., Ayello, J., Morris, E., Harrison, L., van de Ven, C., Goldman, S., Lim, M., Hermiston, M., Perkins, S., & Cairo, M. (2017). Ibrutinib Significantly Enhances Programmed Cell Death and Overall Survival in Burkitt Lymphoma (BL) NSG Xenografts: A Pre-clinical Study. Pediatric Blood & Cancer, 64 (Suppl 1), S33. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/137